Esomeprazole
- PDF / 141,210 Bytes
- 7 Pages / 592.56 x 750.96 pts Page_size
- 111 Downloads / 158 Views
ADIS DRUG PROFILE
© 2008 Adis Data Information BV. All rights reserved.
Esomeprazole In Gastroesophageal Reflux Disease in Children and Adolescents Jamie D. Croxtall, Caroline M. Perry and Gillian M. Keating Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199 1. Pharmacologic Profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200 2. Therapeutic Outcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201 3. Tolerability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203 4. Dosage and Administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203 5. Esomeprazole in Children and Adolescents with Gastroesophageal Reflux Disease: Current Status . . . . . . . . . . . . . . . . . . . . . . . . . . 204
Features and properties of esomeprazole (Nexium®) Featured indication Short-term treatment of gastroesophageal reflux disease (GERD) in children aged 1–11 y and adolescents aged 12–17 y Mechanism of action Proton pump inhibitor
Inhibits gastric acid secretion
Dosage and administration
Abstract ▲ Esomeprazole is the S-isomer of the proton pump inhibitor omeprazole and, administered orally, has been evaluated in the management of gastroesophageal reflux disease (GERD) in children aged 1–11 years and adolescents aged 12–17 years. Further studies in children are ongoing. ▲ In an 8-week, randomized, double-blind, multicenter trial, a significant improvement from baseline in parent-rated GERD symptom scores was seen in children with endoscopically proven GERD aged 1–11 years stratified to receive oral esomeprazole 5 or 10 mg (in those weighing
Data Loading...
